The chairman of Luckin Coffee, touted as China's answer to Starbucks, apologised over its US$310 million accounting fraud, which has led New York's Nasdaq stock exchange to move to delist the company amid waning market trust in Chinese financial reporting.Charles Lu Zhengyao, an angel investor and serial entrepreneur, said he is "deeply disappointed and regret" the delisting decision, which the Nasdaq exchange said was based on public interest concerns over recently disclosed fabricated transactions by company staff that amounted to 2.2 billion yuan (US$310 million)."I have been in deep pain and guilt over the past month," said Lu in a statement published on Chinese social media platform WeChat on Wednesday. "I again apologise to all the investors, staff and clients of Luckin for the terrible impact of the incident."Lu, who also founded China's largest car rental company Car Inc, said he never intended to defraud investors and only wanted to build...
(Bloomberg) -- European stocks turned lower alongside U.S. equity futures on Tuesday as the risk-on mood that kicked-off the week faded. West Texas oil rose for a fourth straight session.The Stoxx Europe 600 Index had opened in the green following news that Germany and France have backed a $546 billion, European Union-wide economic recovery fund. But after strong gains on Monday, the gauge couldn’t hold the move and reversed even as a German investor survey showed a jump in confidence. Contracts for the S&P 500 also pointed to a soft open.Treasuries and most European government bonds climbed, with peripheral yields falling the most on the recovery fund news. Sterling strengthened after the U.K. announced plans for 30 billion pounds ($37 billion) in tariff cuts after Brexit. West Texas crude’s ascent kept it well above $30 a barrel, though it came off highs touched in Asian trade.Riskier assets started the week with...
Tesla’s (TSLA) car registrations in China plummeted 64% in April, compared to March, according to consultancy firm LMC Automotive’s data.Specifically, the electric-vehicle maker’s China registrations dropped to 4,633 units from 12,709 units the previous month. This includes imported cars. “Tesla’s sales in the first month of each quarter are usually lower than the remaining two months” points out Reuters.Meanwhile sales of Tesla’s Model 3 sedan in China plunged 64% in April vs March, according to the China Passenger Car Association (CPCA). Tesla sold 3,635 Model 3 cars in April, a significant decrease from the 10,160 vehicles sold in March.Commenting on the stock after a meeting with Tesla’s investor relations, Emmanuel Rosner at Deutsche Bank, kept to his Hold rating with a $850 price target, despite saying that the company’s message was positive.“While management provided few details about its 2Q/2020 outlook, it believes Fremont production can ramp back up very quickly given its experience in China...
(Bloomberg) -- European stocks turned lower alongside U.S. equity futures on Tuesday as the risk-on mood that kicked-off the week faded. Oil prices rose for a fourth straight session.The Stoxx Europe 600 Index had opened in the green following news that Germany and France have backed a $546 billion, European Union-wide economic recovery fund. But after strong gains on Monday, the gauge couldn’t hold the move and reversed to trade lower. Contracts for the S&P 500 also pointed to a soft open having been up earlier. Asian equities rallied, tracking the big gains on Wall Street yesterday.Treasuries and European government bonds climbed, with peripheral yields falling the most on the recovery fund news. Sterling strengthened after the U.K. announced plans for 30 billion pounds ($37 billion) in tariff cuts after Brexit. West Texas crude’s ascent kept it above $30 a barrel, though it came off highs touched in Asian trade.Riskier assets...
Novavax (NVAX) filed a prospectus to sell up to $250 million of shares of common stock as it prepares to scale up production of its coronavirus vaccine candidate.Shares in Novavax jumped 31% to close at $56.96 in U.S. trading on Monday after their value more than doubled over the past month.The late-stage biotech company, which is in the process of developing a coronavirus antigen vaccine candidate, said that the net proceeds from the sale of common stock will depend on the number of shares actually sold and the offering price for such shares. The company based its calculation on the event that all of the offered shares would be sold at $43.63, the closing price per share on May 15.“We intend to use the net proceeds from this offering for general corporate purposes, including but not limited to working capital, capital expenditures, research and development expenditures, clinical trial expenditures, as well...